Search results
Proprietary Trading Firms to Accelerate Trader Hires - Traders Magazine
Traders Magazine· 1 day agoLondon – 23 May 2024: Almost 90% of proprietary trading firms are planning to increase trading...
Insider Sale: Director Jerome Zeldis Sells 20,000 Shares of PTC
Guru Focus· 36 minutes agoFollowing this transaction, the insider now owns 14,500 shares of the company. PTC Therapeutics Inc is a biopharmaceutical company focused on the discovery ...
Unveiling Deckers Outdoor (DECK)'s Value: Is It Really Priced Ri
Guru Focus· 36 minutes agoWith a market cap of $26.30 billion and a stock price of $1032.9, compared to a GF Value of $599.52, there appears to be a significant discrepancy between the current market price and the estimated ...
Diversified Energy Company PLC (DEC) Beats Stock Market Upswing: What Investors Need to Know
Zacks via Yahoo Finance· 10 hours agoHence, positive alterations in estimates signify analyst optimism regarding the company's business...
Insider Sale: Director Mark Mcfarland Sells 180,000 Shares of California Resources Corp (CRC)
GuruFocus.com via Yahoo Finance· 45 minutes agoOn May 24, 2024, Mark Mcfarland, Director of California Resources Corp (NYSE:CRC), executed a...
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet -...
Benzinga· 11 hours agoEach week, Benzinga’s Stock Whisper Index uses a combination of proprietary data and pattern...
Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi
FOX 59 Indianapolis· 11 hours agoInhibrx, Inc. (Nasdaq: INBX) ("Inhibrx," or the "Company") announced that, at a special meeting (the "Special Meeting"), the Company's stockholders approved ...
UiPath (PATH) Stock Slides as Market Rises: Facts to Know Before You Trade
Zacks via Yahoo Finance· 10 hours agoTherefore, positive revisions in estimates convey analysts' confidence in the company's business...
TSMC (TSM) Outperforms Broader Market: What You Need to Know
Zacks via Yahoo Finance· 10 hours agoAs such, positive estimate revisions reflect analyst optimism about the company's business and...
CRISPR Therapeutics (NASDAQ:CRSP) Trading Down 0.2% After Analyst Downgrade
ETF DAILY NEWS· 5 hours agoCRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) fell 0.2% during mid-day trading on Friday after Citigroup lowered their price target on the stock from $89.00 to $84.00. CRISPR Therapeutics ...